Abstract:The evolution of cancer treatment has provided increasingly targeted strategies both in the upfront and relapsed disease settings. Small‐molecule inhibitors and immunotherapy have risen to prominence with chimeric antigen receptor T‐cells, checkpoint inhibitors, kinase inhibitors, and monoclonal antibody therapies being deployed across a range of solid organ and haematological malignancies. However, novel approaches are required to target transcription factors and oncogenic fusion proteins that are central to cancer biology and have generally eluded successful drug development. Thalidomide analogues causing protein degradation have been a cornerstone of treatment in multiple myeloma, but a lack of in‐depth mechanistic understanding initially limited progress in the field. When the protein cereblon (CRBN) was found to mediate thalidomide analogues' action and CRBN's neo‐targets were identified, existing and novel drug development accelerated, with applications outside multiple myeloma, including non‐Hodgkin's lymphoma, myelodysplastic syndrome, and acute leukaemias. Critically, transcription factors were the first canonical targets described. In addition to broadening the application of protein‐degrading drugs, resistance mechanisms are being overcome and targeted protein degradation is widening the scope of druggable proteins against which existing approaches have been ineffective. Examples of targeted protein degraders include molecular glues and proteolysis targeting chimeras (PROTACs): heterobifunctional molecules that bind to proteins of interest and cause proximity‐induced ubiquitination and proteasomal degradation via a linked E3 ligase. Twenty years since their inception, PROTACs have begun progressing through clinical trials, with early success in targeting the oestrogen receptor and androgen receptor in breast and prostate cancer respectively. This review explores important developments in targeted protein degradation to both treat and study cancer. It also considers the potential advantages and challenges in the translational aspects of developing new treatments. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Driving the Degradation of Oncofusion Proteins for Targeted Cancer Therapy.

Advancing targeted protein degradation for cancer therapy

Targeting the Ubiquitin Pathway for Cancer Treatment

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Protein degradation: expanding the toolbox to restrain cancer drug resistance

Targeting Oncoproteins for Degradation by Small Molecules in Myeloid Leukemia

Targeting chromatin complexes in fusion protein-driven malignancies

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Proteasomal and Lysosomal Degradation for Specific and Durable Suppression of Immunotherapeutic Targets

From the Evasion of Degradation to Ubiquitin-Dependent Protein Stabilization

Opportunities and Challenges in Targeting Ubiquitin Modification and Degradation for Prostate Cancer Therapy

Genetic Fusions Favor Tumorigenesis Through Degron Loss in Oncogenes.

Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical

Dissolution of Oncofusion Transcription Factor Condensates for Cancer Therapy.

The emerging role of targeted protein degradation to treat and study cancer

The role of ubiquitination in tumorigenesis and targeted drug discovery

Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance

Targeting Key Proteins Involved in Transcriptional Regulation for Cancer Therapy: Current Strategies and Future Prospective.

Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Targeting Ferroptosis by Ubiquitin System Enzymes: A Potential Therapeutic Strategy in Cancer

The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?